Join the Acute Myeloid Leukemia group to help and get support from people like you.
Acute Myeloid Leukemia News
Related terms: Acute Granulocytic Leukemia, Acute Myelogenous Leukemia, ANLL, Cancer, Acute Granulocytic Leukemia, Cancer, Acute Myelogenous Leukemia, Cancer, Acute Myeloid Leukemia, Leukemia, Acute Granulocytic, Leukemia, Acute Myelogenous, Leukemia, Acute Myeloid, AML
German Patient is 7th Person Probably Cured of HIV
FRIDAY, July 19, 2024 – A German man has become the seventh person to apparently be cured of HIV, researchers report. The 60-year-old man, referred to as the “next Berlin Patient,” was treated with a...
German Patient is 7th Person Probably Cured of HIV
FRIDAY, July 19, 2024 – A German man has become the seventh person to apparently be cured of HIV, researchers report. The 60-year-old man, referred to as the “next Berlin Patient,” was treated with a...
Ophthalmologic Manifestations of Acute Leukemia Are Heterogeneous
WEDNESDAY, July 17, 2024 – Ophthalmologic manifestations of acute leukemia are heterogeneous and detectable at initial presentation or relapse, according to a study published online July 10 in the...
Posttransplant Cyclophosphamide GVHD Prophylaxis Beneficial in Leukemia
MONDAY, June 24, 2024 – For patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation, posttransplant cyclophosphamide (PTCy) graft-versus-host-disease (GVHD)...
ASCO: Asciminib Has Superior Efficacy to TKIs for Newly Diagnosed Leukemia
WEDNESDAY, June 5, 2024 – For patients with newly diagnosed chronic myeloid leukemia (CML), asciminib shows superior efficacy and a favorable safety profile compared with investigator-selected...
Oldest Adults With Acute Myeloid Leukemia Benefit From Venetoclax
THURSDAY, May 16, 2024 – For older adults with acute myeloid leukemia (AML), venetoclax (VEN) combined with a hypomethylating agent (HMA) is safe and effective and can prolong survival, according to...
Patients Over 80 Still Benefit From Treatment for AML Blood Cancer
TUESDAY, May 14, 2024 – Seniors over 80 with acute myeloid leukemia can safely and effectively take the standard targeted therapy for the blood cancer, a new study finds. The oral drug venetoclax is...
CD7 Expression Tied to Poorer Outcomes With Newly Diagnosed Leukemia
FRIDAY, May 3, 2024 – CD7 expression is associated with poorer outcomes in patients with newly diagnosed acute myeloid leukemia (AML), according to a study published online April 11 in the British...
Improvements Seen in Post-Allo-HCT Outcomes for Seniors With Leukemia
THURSDAY, March 28, 2024 – For older patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (allo-HCT), posttransplant outcomes have improved over time,...
Worse Overall Survival Seen for Adults With Leukemia With CNS Involvement
WEDNESDAY, Feb. 21, 2024 – For adults with acute myeloid leukemia (AML), those with central nervous system (CNS) involvement have worse overall survival, according to a review published in the...
Allogeneic HCT After Primary Induction Failure Beneficial in Leukemia
THURSDAY, Dec. 21, 2023 – For patients with acute myeloid leukemia (AML), immediate allogeneic hematopoietic stem cell transplantation (HCT) after primary induction failure (PIF) offers long-term...
Peripheral Blood Haplo-SCT Feasible for Leukemia Patients 70 Years and Older
WEDNESDAY, Dec. 20, 2023 – For patients with acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS) aged 70 years and older, haploidentical stem cell transplantation (Haplo-SCT) using a...
Fewer Complications Seen With Vitamin C, D Supplementation in AML
WEDNESDAY, Sept. 6, 2023 – For patients with acute myeloid leukemia (AML), supplementation with vitamins C and D during chemotherapy may improve outcomes but may not improve overall survival (OS),...
Precursor to Blood Cancer Is 'Tricky to Diagnose,' Study Shows
WEDNESDAY, Aug. 9, 2023 – New research shows hard-to-diagnose blood disorders called myelodysplastic syndromes/neoplasms (MDS) are often misdiagnosed and a second opinion may be needed. The...
FDA Approves Vanflyta (quizartinib) for Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
TOKYO & BASKING RIDGE, N.J. July 20, 2023 --(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today announced that Vanflyta (quizartinib) has been approved by the U.S. Food and Drug Administration (FDA) in...
Ask a question
To post your own question to this support group, sign in or create an account.